CEM/C2; Leukemia; Human (Homo sapiens) Item ID: ATCCRL2264
| Permits and Restrictions |
View Permits |
|---|---|
| Organism | Homo sapiens, human |
| Cell Type | T lymphoblast |
| Product Format | frozen |
| Morphology | lymphoblast |
| Culture Properties | suspension |
| Biosafety Level |
1
Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country. |
| Disease | acute lymphoblastic leukemia |
| Age | 4 years |
| Gender | female |
| Ethnicity | Caucasian |
| Applications | The cells are approximately 970-fold less sensitive to CPT than the parental CEM cells. CEM/C2 cells exhibit cross resistance to both the water soluble (topotecan) and water insoluble (9-amino-CPT and 10,11-methylenedioxy-CPT) analogs of CPT. CEM/C2 cells are also cross resistant to etoposide, dactinomycin, bleomycin, mitoxantrone, 4'-(9-acridinylamino)methanesulfon-m-anisidide, and the anthracyclines daunorubicin and doxorubicin but retain sensitivity to the Vinca alkaloid vincristine. |
| Storage Conditions | liquid nitrogen vapor temperature |
| Derivation | CEM/C2 is a camptothecin (CPT) resistant derivative of the human T cell leukemia cell line CCRF-CEM (see ATCC CCL-119). |
|---|---|
| Clinical Data | female Caucasian 4 years |
| Comments | CEM/C2 is a camptothecin (CPT) resistant derivative of the human T cell leukemia cell line CCRF-CEM (see ATCC CCL-119). The cell line was selected and subcloned in 1991 for resistance to CPT. The cells are approximately 970-fold less sensitive to CPT than the parental CEM cells. CEM/C2 cells exhibit cross resistance to both the water soluble (topotecan) and water insoluble (9-amino-CPT and 10,11-methylenedioxy-CPT) analogs of CPT. CEM/C2 cells are also cross resistant to etoposide, dactinomycin, bleomycin, mitoxantrone, 4'-(9-acridinylamino)methanesulfon-m-anisidide, and the anthracyclines daunorubicin and doxorubicin but retain sensitivity to the Vinca alkaloid vincristine. CEM/C2 cells display atypical multidrug resistance (MDR), altered topoisomerase I catalytic activity and a unique topoisomerase I mutation (Asn722Ser). Resistance to CPT is stable for up to six months. |
| Complete Growth Medium | The base medium for this cell line is ATCC-formulated RPMI-1640 Medium, ATCC 30-2001. To make the complete growth medium, add the following components to the base medium: fetal bovine serum (ATCC 30-2020) to a final concentration of 10%. |
|---|---|
| Subculturing | Protocol: Cultures can be maintained by addition or replacement of medium. Establish new cultures at 2 X 10 exp5 viable cells/ml and maintain between 1 X 10 exp5 and 2 X 10 exp6. Medium Renewal: Every 2 to 3 days |
| Cryopreservation | Freeze medium: Complete growth medium 95%; DMSO, 5% Storage temperature: liquid nitrogen vapor temperature |
| Culture Conditions | Temperature: 37.0°C |
| STR Profile | Amelogenin: X CSF1PO: 11 D13S317: 11,12 D16S539: 10,13 D5S818: 13 D7S820: 9,8.3 THO1: 6,7 TPOX: 8 vWA: 17,19 |
|---|---|
| Population Doubling Time | 30 hrs |
| Name of Depositor | WG Harker |
|---|---|
| References |
Kapoor R, et al. Altered topoisomerase I expression in two subclones of human CEM leukemia selected for resistance to camptothecin. Oncol. Res. 7: 83-95, 1995. PubMed: 7579731 Fujimori A, et al. Mutation at the catalytic site of topoisomerase I in CEM/C2, a human leukemia cell line resistant to camptothecin. Cancer Res. 55: 1339-1346, 1995. PubMed: 7882333 |